No cardioprotective benefit of ischemic postconditioning in patients with ST-segment elevation myocardial infarction

Nathan B Dwyer1, Yoko Mikami, Darlene Hilland

  • 1Department of Cardiac Sciences and Libin Cardiovascular Institute of Alberta, University of Calgary, Calgary, Alberta, Canada.

Insights

Postconditioning did not significantly improve myocardial salvage or reduce infarct size in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI). Further research with larger sample sizes is needed to explore potential modest benefits.

Area of Science:

  • Cardiology
  • Cardiovascular Research
  • Interventional Cardiology

Background:

  • Postconditioning is a cardioprotective strategy with inconsistent results in human trials for reducing infarct size.
  • Previous studies show variable efficacy, necessitating further investigation in specific patient populations.

Purpose of the Study:

  • To evaluate the effectiveness of postconditioning in enhancing myocardial salvage among patients with acute ST-segment elevation myocardial infarction (STEMI).
  • To determine if postconditioning reduces infarct size in patients undergoing primary percutaneous coronary intervention (PPCI).

Main Methods:

  • A randomized controlled trial involving 102 patients with STEMI undergoing PPCI.
  • Patients were assigned to either a postconditioning protocol or a standard care group.
  • Cardiovascular magnetic resonance imaging was used to assess myocardial necrosis and area at risk post-PPCI.

Main Results:

  • No significant difference in myocardial salvage index between the postconditioning group (42±22%) and the control group (33±21%).
  • Infarct size was not significantly reduced in the postconditioning group (13±7 g/m²) compared to controls (15±8 g/m²).
  • Time-to-reperfusion was similar in both groups, indicating comparable procedural success.

Conclusions:

  • Postconditioning does not significantly increase myocardial salvage or reduce infarct size in STEMI patients undergoing PPCI.
  • The study suggests that postconditioning may not be an effective strategy for this patient group.
  • A potential modest benefit of postconditioning cannot be ruled out due to sample size limitations.
Abstract

Related Concept Videos

Exercise and Cardiovascular Response01:20

Exercise and Cardiovascular Response

Exercise significantly impacts cardiovascular response, which is crucial for understanding patient health and designing effective treatment plans.
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
6.9K
Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
3.9K
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
528
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
812